Xuanwu Hospital, Capital Medical University
Beijing, 100053, China
Location status: Recruiting
NCT Number: NCT06968013
This randomized controlled trial aims to explore the therapeutic effects of Well-Being Therapy (WBT) on patients with Chronic Insomnia accompanied by depressive symptoms.
Interested in participating?
Request Info8 year and older
All sexes
Interventional
Not applicable
Beijing, 100053, China
Location status: Recruiting
According to DSM-IV criteria, approximately 6%-10% of the adult population in industrialized countries suffer from chronic insomnia (CI), characterized by difficulties in initiating or maintaining sleep accompanied by daytime symptoms persisting for at least four weeks. Chronic insomnia often leads to various psychiatric symptoms, with depressive symptoms being among the most common. For patients with CI and comorbid depressive symptoms, the most common treatment involves the use of antidepressant medications. However, while depressive symptoms may improve, insomnia symptoms often persist.
Among non-pharmacological interventions aimed at promoting psychological well-being, Well-Being Therapy (WBT) stands out as a brief and innovative psychotherapeutic approach. WBT is a structured, manualized, short-term therapy that incorporates self-monitoring of well-being episodes through the use of a diary, cognitive restructuring of interfering thoughts and behaviors, and homework assignments.
Previous research has demonstrated the effectiveness of WBT in alleviating stress in populations experiencing 'allostatic load.' This study seeks to evaluate the therapeutic effects of six WBT sessions on individuals with CI and comorbid depressive symptoms.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will undergo Well-Being Therapy (WBT) sessions once daily for 50 minutes over a period of six weeks. The core elements of WBT include prompting participants to identify instances of well-being, contextualize these experiences using a structured diary, and recognize as well as restructure thoughts, beliefs, and behaviors that prematurely disrupt well-being. Additionally, the specific components of the six dimensions of the Psychological Well-Being (PWB) scale-autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, and self-acceptance-are systematically integrated into different therapy sessions
Participants will receive Sleep Hygiene Education (SHE) alone for 6 weeks. SHE involves education on maintaining consistent sleep schedules, creating a sleep-conducive environment, reducing stimulant use (e.g., caffeine, alcohol), and promoting healthy daily routines to improve sleep quality.
Time frame: Baseline and Week 6
The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire designed to evaluate sleep quality over a one-month period. It consists of 19 items grouped into seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.
Each component is scored on a scale of 0 to 3, and the total score ranges from 0 to 21, with higher scores indicating poorer sleep quality.
Time frame: Baseline, 3 months, 6 months, and 12 months
As mentioned in the previous text.
Time frame: Baseline, Week 6, 3 months, 6 months, and 12 months
The Hamilton Depression Scale-17 (HAMD-17) is a clinician-administered tool designed to assess the severity of depressive symptoms over the past week. It consists of 17 items that evaluate various aspects of depression, such as mood, guilt, insomnia, anxiety, and physical symptoms. Each item is scored on a scale, and the total score reflects the severity of depression.
The scoring criteria are as follows:
0-7: Normal (not depressed) 8-13: Mild depression 14-18: Moderate depression 19-22: Severe depression 23 or above: Very severe depression.
Time frame: Baseline, Week 6, 3 months, 6 months, and 12 months
The Beck Depression Inventory-II (BDI-II) is a self-report questionnaire designed to assess the severity of depressive symptoms. It consists of 21 items, each scored on a scale from 0 to 3, with a total score ranging from 0 to 63. The scoring interpretation is as follows:
0-13: Minimal depression 14-19: Mild depression 20-28: Moderate depression 29-63: Severe depression
Time frame: Baseline, Week 6, 3 months, 6 months, and 12 months
The scale contains 21 items and uses a 4-point scale method, with a total score of 15-25 as mild anxiety, 26-35 as moderate anxiety, and 36 or more as severe anxiety
Time frame: Baseline, Week 6, 3 months, 6 months, and 12 months
The Patient Health Questionnaire-4 (PHQ-4) is a brief screening tool designed to assess symptoms of anxiety and depression. It consists of four items, with two questions focusing on anxiety and two on depression. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 12. The scoring interpretation is as follows:
0-2: None (minimal distress) 3-5: Mild distress 6-8: Moderate distress 9-12: Severe distress
Time frame: Baseline, Week 6, 3 months, 6 months, and 12 months
The 36-Item Short Form Health Survey (SF-36) is a widely used questionnaire designed to measure health-related quality of life. It evaluates eight domains: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. Each domain is scored on a scale from 0 to 100, with higher scores indicating better health status.
Time frame: Baseline, Week 6, 3 months, 6 months, and 12 months
The Snaith-Hamilton Pleasure Scale (SHAPS) is a self-report questionnaire designed to measure anhedonia, which is the reduced ability to experience pleasure. It consists of 14 items assessing various aspects of enjoyment in daily life, such as hobbies, social interactions, and sensory experiences. Each item is scored on a scale, and the total score ranges from 0 to 14, with higher scores indicating greater levels of anhedonia.
Time frame: Baseline, Week 6, 3 months, 6 months, and 12 months
The Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS) is a self-report questionnaire designed to assess maladaptive beliefs and attitudes related to sleep. It consists of items scored on a scale, typically using a visual analogue format or numerical ratings. The total score is calculated by averaging responses across all items, with higher scores indicating more dysfunctional beliefs about sleep.
Time frame: Baseline, Week 6, 3 months, 6 months, and 12 months
The scale is divided into 7 sections with a total score of 0-28, with higher scores indicating more severe insomnia. The degree of insomnia is classified according to the scores: 0-7 indicates no insomnia, 8-14 is mild insomnia, 15-21 is moderate insomnia, and 22-28 is severe insomnia.
Time frame: Baseline, Week 6, 3 months, 6 months, and 12 months
The Self-rated Sleep Severity (0-10 Numeric Rating Scale) is a simple tool used to assess an individual's perception of their sleep quality or severity of sleep-related issues. Respondents rate their sleep on a scale from 0 to 10, where 0 represents no sleep problems and 10 indicates the most severe sleep difficulties.
Time frame: Throughout study duration up to 12 months
Contact information is provided by the study sponsor or research team.
Xuanwu Hospital, Beijing
Other
Investigating on the Efficacy of Well-Being Therapy (WBT) for Chronic Insomnia (CI) With Depressive Symptoms
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07429578
Anxiety Disorders, Chronic Insomnia
São Paulo, Brazil
View Trial DetailsNCT07542756
Chronic Insomnia, Chronic Insomnia Disorder
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07216261
Chronic Insomnia, Dyssomnias
Durham, North Carolina, United States
View Trial DetailsNCT07156383
Chronic Insomnia, Dyssomnias
Notre Dame, Indiana, United States
View Trial Details